-

$undefined

N/A

(N/A)

Artiva Biotherapeutics NasdaqGM:ARTV Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Location: 5505 Morehouse Drive, San Diego, CA, 92121, United States | Website: https://www.artivabio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-104.9M

Cash

166M

Avg Qtr Burn

-14.95M

Short % of Float

23.58%

Insider Ownership

19.99%

Institutional Own.

89.73%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AlloNK® (AB-101) + rituximab Details Rheumatoid arthritis, Pemphigus vulgaris, Granulomatosis with polyangiitis/microscopic polyangiitis, Systemic lupus erythematosus	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AlloNK® (AB-101) + rituximab Details B-cell non-Hodgkin’s lymphoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AlloNK® (AB-101) + rituximab or obinutuzumab Details Systemic lupus erythematosus (SLE) with or without lupus nephritis (LN)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.